Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27031148 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Silvia Pomella und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy. Hauptthemen laut MEDLINE: Fibronectins, Breast Neoplasms, Mouth Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'università e della ricerca, Italian Ministry of University and Research.
Abstract (Originalsprache)
The tightly controlled and transient acquisition of a motile phenotype by otherwise static epithelial cells (epithelial–mesenchymal transition, EMT) enables the repair of a damaged epithelium. Conversely, a persistent, dysregulated, and exacerbated EMT characterizes epithelial malignancies such as breast carcinoma (BC) and oral squamous cell carcinoma (OSCC), being key for their metastasis and for their escaping anti-tumor immune responses. Herein, we investigated the relationship between EMT signatures and immune cell infiltration across OSCC and metastatic BC with the aim to identify prognostic markers and/or therapeutic targets common to both these malignancies, or unique to OSCC or BC. To this end, we analyzed publicly available transcriptomic datasets to identify coding genes involved in EMT with strong correlation to immune cell signatures. The methodology consisted of data selection, correlation analysis, signature overlap determination, and validation using independent databases. Results indicated that in both OSCC and BC the expression of EMT-related genes is strongly associated with that of immunosuppressive and pro-tumor macrophages. Notably, the FN1 gene coding for the extracellular matrix glycoprotein fibronectin (FN) emerged as the EMT gene common to either tumor types. In confirmation of this, FN protein levels were higher in OSCC and BC tissues than in their normal counterparts. Given FN capability of favoring tumor invasion and metastasis while hindering antitumor immune responses, these data encourage the development of FN antagonists to be used as an adjunct to conventional therapy in the treatment of both OSCC and BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
- Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy.
- School of Medicine, Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy.
ORCID-Profile: Silvia Pomella, Roberto Bei, Ombretta Melaiu, Giovanni Barillari
Förderung
- Ministero dell'università e della ricerca
- Italian Ministry of University and Research
Zitieren
APA
Pomella, S., Bei, R., Melaiu, O., & Barillari, G. (2026). Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031148
Vancouver
Pomella S, Bei R, Melaiu O, Barillari G. Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031148
BibTeX
@article{Pomella2026,
author = {Pomella, Silvia and Bei, Roberto and Melaiu, Ombretta and Barillari, Giovanni},
title = {Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27031148}
}
EUVIMED